We are trying to prevent Metastasis.
Majority of patients are 15-20 years of age

Current Treatment for Osteosarcoma in resection of the solid tumor, which usually occurs in the leg or the arm. This can include the entire limb, or an internal prosthesis is used for limb sparing.

The patient then receives radiation and what is considered the worse chemotherapy regimen in cancer: 8-9 months of Cisplatin, Doxorubicin and Methotrexate. Ten (10) percent of Osteosarcoma patients don’t survive this treatment, and those that do, have a 50% chance of the cancer returning as Metastasis to the brain or lungs.

Of those patients that Metastasis, there is an approximate 13% survival.

OS Therapies’ HER2 Immunotherapy is capable of stimulating the body’s immune system to seek out, identify and destroy the micro-metastasis or “cancer seeds” that survived the initial radiation and chemotherapy.

By giving the body a weakened biologic infection of Listeria, the body reacts secreting T-cells from the lymph nodes that go out and find the “cancer seeds” and destroy them.

Platform Technology #1: OST – HER2

As opposed to chemotherapy and radiation, by exposing the body to a weakened form of Listeria and then shutting it down with antibiotics, we have stimulated the body’s natural immune system with significantly less side-effects.

All of us have cancer in our bodies – it is the immune system that is identifying and shutting it down before it becomes a medical issue.

T cells hunt down the cancer cells and attacks them directly, killing them by punching holes

Intravenous OST-HER2 vector rapidly cleared by immune system’s Antigen Presenting Cells (APCs)

APCs  are strongly activated and generate potent HER2 specific T cells from within the patient

Cancer cells contents spill out and additional cancer targets are revealed

T cells proliferate, travel through the blood and are attracted to the Micro-Metastasis

New targets are taken up by the immune system

T cells are generated against the new targets, repeating the cycle and extending the treatment effects

T cells then infiltrate and accumulate within the cancer cells- Tregs and MDSCs protecting the tumor are reduced

Platform Technology #2: OST - TDC

• Smaller targeting moieties/ligands provide better tumor penetration
• SiLinkers rapidly release payloads inside targeted cancer cells and in the acidic microenvironments of tumors
• Conditionally Active Payloads (CAPs) only cross cell membranes and kill cancer cells under the same acidic conditions that our SiLinkers cleave.  CAPs are trapped and concentrated in tumor cells

Paul Romness, MHP | Co-Founder and CEO

• 30+ years BioPharma experience, including Johnson & Johnson, Amgen and Boehringer Ingelheim

Robert Petit, PhD | Chief Medical and Scientific Officer

• 30+ years BioPharma experience, including Bristol-Myers Squibb, Pharmacia and Advaxis

Jutta Wanner, PhD | Chief Technology Officer

• 20+ years BioPharma experience, including Hoffman-LaRoche, Coferon and BlinkBio

Chris Acevedo, CPA | Interim CFO

• 30+ years experience